Biotechnology from bench to business

• Follow GEN on:
• Login | Register | Subscribe

• ADME/Tox
• Automation
• Bioprocess Scale-Up
• Bioreactors
• Biosimilars
• Cell Culture
• Cell-Based Assays
• Contract Manufacturing
• Gene Therapy
• High-Throughput Screening
• Immunoassay
• Induced Pluripotent Stem Cells
• Informatics
• Liquid Handling
• Protein Characterization
• Protein Detection
• Regenerative Medicine
• RNAi/siRNA
• Stem Cells
• Western Blot

• GEN Articles

• More »

• Legal Affairs: Isolated Genes Remain Patentable
  Federal Circuit Revisits Issue in Light of Supreme Court’s Mayo Ruling
• BioPerspectives: Mammography Guidelines - Bring on the Controversy!
  
• Feature Articles: Personalizing Cancer Treatment
  Answers Likely to Be Found in Unraveling Genomic and Epigenomic Complexities
• Point of View: Substantive Progress Is Being Made in Breast Cancer Survival
  Battles in the War on Cancer Are Being Won

• Insight & Intelligence™

• More »

• The Tumor Microenvironment as a Drug Target, Part II
  May 10, 2013
  In the search for new targets, cancer researchers are taking a closer look at the cellular support networks that allow tumors to survive.
• Literature Review: Which Drug Combination Will Unlock Triple-Negative Breast Cancer?
  April 26, 2013
  Researchers describe a strategy for treating TNBC that combines noncompetitive antibodies to achieve degradation of EGFR and tumor inhibition.
• Genome Testing Reduces Overtreatment
  November 29, 2012
  Study after study has shown that molecular diagnostics can help oncologists more effectively treat patients.
• 15 Breast Cancer Drugs in the Pipeline Right Now
  November 27, 2012
  Which candidates are on their way from the lab to the medicine chests of thousands?
• Avastin Label Changes Reignites Debate: Is OS or PFS the Better Regulatory Endpoint?
  December 13, 2011
  A recent panel discussion set the stage for defining standards for drug approval as separate from those for treatment decisions.

• GEN News Highlights

• More »

• Sorrento, Igdrasol Secure Exclusive E.U. Distribution Rights to Cancer Drug
  
• Turning Off Cancer’s “Master Regulator”
  
• Triple Threat: Gene Controls Three Diseases
  
• New Computational Model for Breast Cancer Survival
  
• In Gene Patenting Case, a Myriad of Analogies
  

• GEN Podcasts

• More »

• FIRST USE OF NANOSENSORS TO MEASURE CANCER BIOMARKERS IN BLOOD
  - Interview with Mark Reed, Ph.D., Harold Hodgkinson Chair of Engineering and Applied Science, Yale University, and Associate Director of the Yale Institute for Nanoscience and Quantum Engineering

• BLOG Biotech

• More »

• Mammography Guidelines - Bring on the Controversy!
  

• New Products

• More »

Mirus Bio Transfection Reagent TransIT®-BrCa transfection reagent is a dedicated breast cancer cell-line specific reagent that can help researchers achieve high expression levels in breast cancer cell types including MCF-7, MDA-MB-231, MDA-MB-453, MDA-MB-468, and T47D. It c